The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications

European Journal of Heart Failure

Volumn 18, Issue 7, 2016, Pages 762-773

  Stugiewicz, Magdalena ^a   Tkaczyszyn, Michał ^a,b   Kasztura, Monika ^a   Banasiak, Waldemar ^b   Ponikowski, Piotr ^a,b   Jankowska, Ewa A ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MILITARY HOSPITAL   (Poland)

Author keywords

Chronic obstructive pulmonary disease; Exercise intolerance; Heart failure; Iron deficiency; Skeletal muscles

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IRON;

AEROBIC METABOLISM; ANEMIA; CELL DAMAGE; CELL ENERGY; CELL LEVEL; CELL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; ENERGY CONSUMPTION; EXERCISE; HEART FAILURE; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; METABOLIC DISORDER; MITOCHONDRION; MUSCULOSKELETAL FUNCTION; MYOPATHY; NONHUMAN; PHYSICAL ACTIVITY; PLASTICITY; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY MYOPATHY; REVIEW; SKELETAL MUSCLE; SKELETAL MUSCLE CELL; SKELETAL MUSCLE PLASTICITY; SKELETAL MYOPATHY;

EID: 84979020293     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.467     Document Type: Review

References (119)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137–1146.
2. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(5 Suppl):121S–126S.
3. Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994;72(2Suppl):S36–S39.
4. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr 2000;71:1033–1047.
5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165–1185.
6. Zizola C, Schulze PC. Metabolic and structural impairment of skeletal muscle in heart failure. Heart Fail Rev 2013;18:623–630.
7. Lipkin DP, Jones DA, Round JM, Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol 1988;18:187–195.
8. Rabinovich RA, Vilaró J. Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010;16:123–133.
9. Buller NP, Jones D, Poole-Wilson PA. Direct measurement of skeletal muscle fatigue in patients with chronic heart failure. Br Heart J 1991;65:20–24.
10. Minotti JR, Christoph I, Oka R, Weiner MW, Wells L, Massie BM. Impaired skeletal muscle function in patients with congestive heart failure. Relationship to systemic exercise performance. J Clin Invest 1991;88:2077–2082.
11. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(2S-2):568S–579S.
12. Galy B, Ferring-Appel D, Sauer SW, Kaden S, Lyoumi S, Puy H, Kölker S, Gröne HJ, Hentze MW. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab 2010;12:194–201.
13. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2013;61:599–610.
14. Puntarulo S. Iron, oxidative stress and human health. Mol Aspects Med 2005;26:299–312.
15. Iyengar MR. Creatine kinase as an intracellular regulator. J Muscle Res Cell Motil 1984;5:527–534.
16. Atalay M, Hänninen OOP. Muscle energy metabolism. In Atalay M, Hänninen O, ed. Encyclopedia of Life Support Systems: Physiology and Maintenance, Vol. IV. Eolss Publishers Company Limited: 2009; p. 26–47.
17. Hänninen O, Atalay M. Oxidative metabolism in skeletal muscle. In: Reznick AZ, Packer L, Sen CK, Holloszy JO, Jackson MJ, eds. Oxidative Stress in Skeletal Muscle. MCBU Molecular and Cell Biology Updates. Springer: Berlin; 1998. p.29–42.
18. Westerblad H, Bruton JD, Katz A. Skeletal muscle: energy metabolism, fiber types, fatigue and adaptability. Exp Cell Res 2010;316:3093–3099.
19. Bottinelli R, Reggiani C. Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol 2000;73:195–262.
20. Polla B, D'Antona G, Bottinelli R, Reggiani C. Respiratory muscle fibres: specialisation and plasticity. Thorax 2004;59:808–817.
21. Mettauer B, Zoll J, Garnier A, Ventura-Clapier R. Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflugers Arch Eur J Physiol 2006;452:653–666.
22. Baldwin KM, Haddad F. Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. J Appl Physiol 2001;90:345–357.
23. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 1996;76:371–423.
24. Gollnick PD, Armstrong RB, Saubert CW 4th, Piehl K, Saltin B. Enzyme activity and fiber composition in skeletal muscle of untrained and trained men. J Appl Physiol 1972;33:312–319.
25. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009;81:412–419.
26. Traczyk WZ, Trzebski A, eds. Fizjologia Człowieka z Elementami Fizjologii Stosowanej i Klinicznej. Warszawa: Wydawnictwo Lekarskie PZWL; 2007.
27. Spriet LL. Anaerobic metabolism in human skeletal muscle during short-term, intense activity. Can J Physiol Pharmacol 1992;70:157–165.
28. Murray RK, Granner DK, Rodwell VW, eds. Harper's Illustrated Biochemistry, 27th ed. New York: The McGraw-Hill Companies; 2006.
29. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise: how is it regulated? Physiology 2005;20:260–270.
30. Heinonen I, Saltin B, Kemppainen J, Sipilä HT, Oikonen V, Nuutila P, Knuuti J, Kalliokoski K, Hellsten Y. Skeletal muscle blood flow and oxygen uptake at rest and during exercise in humans: a PET study with nitric oxide and cyclooxygenase inhibition. Am J Physiol Heart Circ Physiol 2011;300:H1510–H1517.
31. Hultman E. Fuel selection, muscle fibre. Proc Nutr Soc 1995;54:107–121.
32. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD. Role of fatty acid uptake and fatty acid β-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim Biophys Acta 2010; 1801:1–22.
33. Boulton F. The myoglobin content of human skeletal muscle. Br J Haematol 1973;25:281.
34. Robach P, Cairo G, Gelfi C, Bernuzzi F, Pilegaard H, Viganò A, Santambrogio P, Cerretelli P, Calbet JA, Moutereau S, Lundby C. Strong iron demand during hypoxia-induced erythropoiesis is associated with down-regulation of iron-related proteins and myoglobin in human skeletal muscle. Blood 2007;109:4724–4731
35. Ohira Y, Gill SL. Effects of dietary iron deficiency on muscle fiber characteristics and whole-body distribution of hemoglobin in mice. J Nutr 1983;113:1811–188.
36. Kuninger D, Kuns-Hashimoto R, Kuzmickas R, Rotwein P. Complex biosynthesis of the muscle-enriched iron regulator RGMc. J Cell Sci 2006;119:3273–3283.
37. Gkouvatsos K, Wagner J, Papanikolaou G, Sebastiani G, Pantopoulos K. Conditional disruption of mouse Hfe2 gene: mMaintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin. Hepatology 2011;54:1800–1807.
38. Hentze M, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010;142:24–38.
39. Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol 2013;20:208–214.
40. Zhang AS. Control of systemic iron homeostasis by the hemojuvelin-hepcidin axis. Adv Nutr 2010;1:38–45.
41. Polonifi A, Politou M, Kalotychou V, Xiromeritis K, Tsironi M, Berdoukas V, Vaiopoulos G, Aessopos A. Iron metabolism gene expression in human skeletal muscle. Blood Cells Mol Dis 2010;45:233–237.
42. Sekyere EO, Dunn LL, Richardson DR. Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. Biochim Biophys Acta 2005; 1722:131–142.
43. Masso-Silva J, Diamond G, Macias-Rodriguez M, Ascencio F. Genomic organization and tissue-specific expression of hepcidin in the pacific mutton hamlet, Alphestes immaculatus (Breder, 1936). Fish Shellfish Immunol 2011;31:1297–1302.
44. Anderson CP, Shen M, Eisenstein RS, Leibold EA. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta 2012; 1823:1468–1483.
45. Guo B, Yu Y, Leibold EA. Iron regulates cytoplasmic levels of a novel iron-responsive element-binding protein without aconitase activity. J Biol Chem 1994;269:24252–24260.
46. Philpott CC, Leidgens S, Frey AG. Metabolic remodeling in iron-deficient fungi. Biochim Biophys Acta 2012; 1823:1509–1520.
47. Ackrell B, Maguire JJ, Dallman PR, Kearney EB. Effect of iron deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria. J Biol Chem 1984;259:10053–10059.
48. Cartier LJ, Ohira Y, Chen M, Cuddihee RW, Holloszy JO. Perturbation of mitochondrial composition in muscle by iron deficiency. J Biol Chem 1986;261:13827–13832.
49. Mackler B, Grace R, Finch CA. Iron deficiency in the rat: effects on oxidative metabolism in distinct types of skeletal muscle. Pediatr Res 1984;18:499–500.
50. Finch CA, Miller LR, Inamdar AR, Person R, Seiler K, Mackler B. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447–453.
51. Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol 1982;242:E418–E427.
52. Henderson SA, Dallman PR, Brooks GA. Glucose turnover and oxidation are increased in the iron-deficient anemic rat. Am J Physiol 1986;250:E414–E421.
53. Ohira Y, Hegenauer J, Strause L, Chen CS, Saltman P, Beinert H. Mitochondrial NADH dehydrogenase in iron-deficient and iron-repleted rat muscle: an EPR and work performance study. Br J Haematol 1982;52:623–630.
54. Thompson CH, Green YS, Ledingham JG, Radda GK, Rajagopalan B. The effect of iron deficiency on skeletal muscle metabolism of the rat. Acta Physiol Scand 1993;147:85–90.
55. Ohlendieck K. Proteomic identification of biomarkers of skeletal muscle disorders. Biomark Med 2013;7:169–186.
56. Zick M, Rabl R, Reichert AS. Cristae formation—linking ultrastructure and function of mitochondria. Biochim Biophys Acta 2009; 1793:5–19.
57. Maguire JJ, Davies KJ, Dallman PR, Packer L. Effects of dietary iron deficiency of iron-sulfur proteins and bioenergetic functions of skeletal muscle mitochondria. Biochim Biophys Acta 1982;679;210–220.
58. Hagler L, Askew EW, Neville JR, Mellick PW, Coppes RI Jr, Lowder JF Jr. Influence of dietary iron deficiency on hemoglobin, myoglobin, their respective reductases, and skeletal muscle mitochondrial respiration. Am J Clin Nutr 1981;34:2169–2177.
59. Merrill JF, Thomson DM, Hardman SE, Hepworth SD, Willie S, Hancock CR. Iron deficiency causes a shift in AMP-activated protein kinase (AMPK) subunit composition in rat skeletal muscle. Nutr Metab (Lond) 2012;9:104.
60. Liew YF, Shaw NS. Mitochondrial cysteine desulfurase iron–sulfur cluster S and aconitase are post-transcriptionally regulated by dietary iron in skeletal muscle of rats. J Nutr 2005;135:2151–2158.
61. O'Dell BL, Sunde RA. Handbook of Nutritionally Essential Mineral Elements. Boca Raton, FL: CRC Press; 1997
62. Han DH, Hancock CR, Jung SR, Higashida K, Kim SH, Holloszy JO. Deficiency of the mitochondrial electron transport chain in muscle does not cause insulin resistance. PLoS One 2011;6:e19739.
63. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000;88:2219–2226.
64. McGee SL, Mustard KJ, Hardie DG, Baar K. Normal hypertrophy accompanied by phosphoryation and activation of AMP-activated protein kinase alpha1 following overload in LKB1 knockout mice. J Physiol 2008;586:1731–1741.
65. Haas JD, Brownlie T 4th. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131(2S-2):676S–688S; discussion 688S-690S.
66. Perkkiö MV, Jansson LT, Brooks GA, Refino CJ, Dallman PR. Work performance in iron deficiency of increasing severity. J Appl Physiol 1985;58:1477–1480.
67. Davies KJ, Donovan CM, Refino CJ, Brooks GA, Packer L, Dallman PR. Distinguishing effects of anemia and muscle iron deficiency on exercise bioenergetics in the rat. Am J Physiol 1984;246:E535–E543.
68. Edgerton VR, Bryant SL, Gillespie CA, Gardner GW. Iron deficiency anemia and physical performance and activity of rats. J Nutr 1972;102:381–399.
69. Ohira Y, Koziol BJ, Edgerton VR, Brooks GA. Oxygen consumption and work capacity in iron-deficient anemic rats. J Nutr 1981;111:17–25.
70. Beard J, Tobin B. Iron status and exercise. Am J Clin Nutr 2000;72(2 Suppl):594S–597S.
71. Brownlie T 4th, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002;75:734–742.
72. Burden RJ, Morton K, Richards T, Whyte GP, Pedlar CR. Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A meta-analysis. Br J Sports Med 2015;49:1389–1397.
73. Hinton PS, Giordano C, Brownlie T, Haas JD. Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol 2000;88:1103–1111.
74. Hinton PS, Sinclair LM. Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007;61:30–39.
75. Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Haas JD. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 2003;77:441–448.
76. Brownlie T 4th, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004;79:437–443.
77. Thompson CH, Kemp GJ, Taylor DJ, Radda GK, Rajagopalan B. No evidence of mitochondrial abnormality in skeletal muscle of patients with iron-deficient anaemia. J Intern Med 1993;234:149–154.
78. Celsing F, Blomstrand E, Werner B, Pihlstedt P, Ekblom B. Effects of iron deficiency on endurance and muscle enzyme activity in man. Med Sci Sports Exerc 1986;18:156–161.
79. Gosker HR, Hesselink MK, Duimel H, Ward KA, Schols AM. Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J 2007;30:73–79.
80. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr 2000;71:1033–1047.
81. Piepoli MF, Kaczmarek A, Francis DP, Davies LC, Rauchhaus M, Jankowska EA, Anker SD, Capucci A, Banasiak W, Ponikowski P. Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation 2006;114:126–134.
82. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347–360.
83. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992;85:1364–1373.
84. Buller NP, Jones D, Poole-Wilson PA. Direct measurement of skeletal muscle fatigue in patients with chronic heart failure. Br Heart J 1991;65:20–24.
85. Harridge SD, Magnusson G, Gordon A. Skeletal muscle contractile characteristics and fatigue resistance in patients with chronic heart failure. Eur Heart J 1996;17:896–901.
86. Drexler H, Riede U, Münzel T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992;85:1751–1759.
87. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990;81:518–527.
88. Sabbah HN, Hansen-Smith F, Sharov VG, Kono T, Lesch M, Gengo PJ, Steffen RP, Levine TB, Goldstein S. Decreased proportion of type I myofibers in skeletal muscle of dogs with chronic heart failure. Circulation 1993;87:1729–1737.
89. Chati Z, Zannad F, Robin-Lherbier B, Escanye JM, Jeandel C, Robert J, Aliot E. Contribution of specific skeletal muscle metabolic abnormalities to limitation of exercise capacity in patients with chronic heart failure: a phosphorus 31 nuclear magnetic resonance study. Am Heart J 1994;128:781–792.
90. Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, Wilson JR. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation 1989;80:1338–1346.
91. Mancini DM, Henson D, LaManca J, Levine S. Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 1992;86 909–918.
92. Mancini DM, Ferraro N, Tuchler M, Chance B, Wilson JR. Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonance. Am J Cardiol 1988;62:1234–1240.
93. Mettauer B, Zoll J, Sanchez H, Lampert E, Ribera F, Veksler V, Bigard X, Mateo P, Epailly E, Lonsdorfer J, Ventura-Clapier R. Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. J Am Coll Cardiol 2001;38:947–954.
94. Massie BM, Conway M, Yonge R, Frostick S, Sleight P, Ledingham J, Radda G, Rajagopalan B. 31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol 1987;60:309–315.
95. Agusti A, Soriano JB. COPD as a systemic disease. COPD 2008;5:133–138.
96. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:629–634.
97. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997;337:1799–1806.
98. Puente-Maestu L, Pérez-Parra J, Godoy R, Moreno N, Tejedor A, González-Aragoneses F, Bravo JL, Alvarez FV, Camaño S, Agustí A. Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients. Eur Respir J 2009;33:1045–1052.
99. Wuyam B1, Payen JF, Levy P, Bensaïdane H, Reutenauer H, Le Bas JF, Benabid AL. Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease. Eur Respir J 1992;5:157–162.
100. Payen JF, Wuyam B, Levy P, Reutenauer H, Stieglitz P, Paramelle B, Le Bas JF. Muscular metabolism during oxygen supplementation in patients with chronic hypoxemia. Am Rev Respir Dis 1993;147:592–598.
101. Josiak K1, Jankowska EA, Piepoli MF, Banasiak W, Ponikowski P. Skeletal myopathy in patients with chronic heart failure: significance of anabolic–androgenic hormones. J Cachexia Sarcopenia Muscle 2014;5:287–296.
102. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–869.
103. Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, Zannad F, Laperche T, Leclercq C, Concas V, Duvillié L, Darné B, Anker S, Mebazaa A. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 2014;16:984–991.
104. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575–582.
105. Yeo TJ, Yeo PS, Ching-Chiew Wong R, Ong HY, Leong KT, Jaufeerally F, Sim D, Santhanakrishnan R, Lim SL, M Y Chan M, Chai P, Low AF, Ling LH, Ng TP, Richards AM, Lam CS. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail 2014;16:1125–1132.
106. Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J, Rozentryt P, Polonski L, van Veldhuisen DJ, Ponikowski P, Comin-Colet J, van der Meer P. The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences. Eur J Heart Fail 2014;16:655–662.
107. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014;14:24.
108. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011;17:899–906.
109. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241–1251.
110. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail 2015;17:248–262.
111. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225–1227.
112. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657–1665.
113. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.
114. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–668.
115. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103–112.
116. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013;168:3439–3442.
117. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013;15:1267–1276.
118. Van Craenenbroeck EM, Conraads VM, Greenlaw N, Gaudesius G, Mori C, Ponikowski P, Anker SD. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Eur J Heart Fail 2013;15:756–762.
119. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD; FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 2015;17:329–339.